Trade Sage Therapeutics, Inc. - SAGE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.11 |
| Open | 7.23 |
| 1-Year Change | -67.2% |
| Day's Range | 7.13 - 7.5 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 7.28 | 0.13 | 1.82% | 7.15 | 7.52 | 7.13 |
| Feb 20, 2025 | 7.11 | 0.13 | 1.86% | 6.98 | 7.19 | 6.97 |
| Feb 19, 2025 | 7.02 | -0.08 | -1.13% | 7.10 | 7.15 | 6.99 |
| Feb 18, 2025 | 7.15 | 0.03 | 0.42% | 7.12 | 7.22 | 7.10 |
| Feb 14, 2025 | 7.11 | -0.02 | -0.28% | 7.13 | 7.20 | 7.03 |
| Feb 13, 2025 | 7.15 | 0.09 | 1.27% | 7.06 | 7.22 | 6.94 |
| Feb 12, 2025 | 7.10 | 0.05 | 0.71% | 7.05 | 7.23 | 7.01 |
| Feb 11, 2025 | 7.14 | 0.03 | 0.42% | 7.11 | 7.22 | 7.02 |
| Feb 10, 2025 | 7.21 | -0.12 | -1.64% | 7.33 | 7.37 | 7.21 |
| Feb 7, 2025 | 7.21 | 0.02 | 0.28% | 7.19 | 7.28 | 7.16 |
| Feb 6, 2025 | 7.25 | 0.02 | 0.28% | 7.23 | 7.29 | 7.15 |
| Feb 5, 2025 | 7.20 | 0.00 | 0.00% | 7.20 | 7.27 | 7.12 |
| Feb 4, 2025 | 7.20 | -0.01 | -0.14% | 7.21 | 7.27 | 7.15 |
| Feb 3, 2025 | 7.21 | 0.16 | 2.27% | 7.05 | 7.27 | 6.93 |
| Jan 31, 2025 | 7.21 | -0.07 | -0.96% | 7.28 | 7.36 | 7.14 |
| Jan 30, 2025 | 7.31 | 0.01 | 0.14% | 7.30 | 7.37 | 7.24 |
| Jan 29, 2025 | 7.30 | 0.08 | 1.11% | 7.22 | 7.43 | 7.17 |
| Jan 28, 2025 | 7.30 | -0.07 | -0.95% | 7.37 | 7.47 | 7.23 |
| Jan 27, 2025 | 7.41 | 0.21 | 2.92% | 7.20 | 7.52 | 7.18 |
| Jan 24, 2025 | 7.07 | 0.12 | 1.73% | 6.95 | 7.08 | 6.87 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Sage Therapeutic Company profile
About SAGE Therapeutics Inc
SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, SAGE Therapeutics Inc revenues decreased 99% to $6.3M. Net loss totaled $457.9M vs. income of $606.1M. Revenues reflect Collaboration revenue decrease from $1.11B to $0K, Product decrease of 6% to $6.3M. Net loss reflects Stock-based Compensation in R&D increase of 17% to $49.7M (expense), Stock-based Compensation in SGA increase of 6% to $54.9M (expense), Other income (expense).
Equity composition
Common Stock, $0.0001 Par, 07/14, auth. 120M shares,. 24,961,926 issd,. Insiders owns approx. 20.03%.
| Industry: | Bio Therapeutic Drugs |
215 1st St
CAMBRIDGE
MASSACHUSETTS 02142
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com